TrialBMC cancer2021

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.

Dena Firouzabadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.